Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.63 |
| ▸ | NQO2 | P16083 | 1/20 | 0.62 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HTR1D | P28221 | 1/20 | 0.51 |
| ▸ | HTR1B | P28222 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | IFNAR1 | P17181 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27581438 | 0.98 | MTNR1A (0.61) | MTNR1ANQO2TAAR1KDM4EALDH1A1 | |
| SCHEMBL14105953 | 0.87 | SLC6A4 (0.57) | MTNR1ANQO2HTR1DHTR1BSLC6A4 | |
| SCHEMBL8794788 | 0.83 | HPGD (0.64) | MTNR1ANQO2HTTHPGDCYP1A2 | |
| SCHEMBL8858591 | 0.81 | NQO2 (0.58) | MTNR1ANQO2HTR2AHTR1BHPGD | |
| SCHEMBL3047898 | 0.80 | CYP1A2 (0.62) | MTNR1ANQO2ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL24821313 | 0.80 | HPGD (0.56) | MTNR1ANQO2HTR2AHPGDIFNAR1 | |
| SCHEMBL3637276 | 0.80 | MTNR1A (0.57) | MTNR1ANQO2HTTHPGDCYP1A2 | |
| SCHEMBL19553634 | 0.80 | MTNR1A (0.62) | MTNR1ANQO2ALDH1A1HTR1AHTT | |
| SCHEMBL29061337 | 0.80 | MTNR1A (0.57) | MTNR1ANQO2HTTHPGDCYP1A2 | |
| SCHEMBL2255099 | 0.80 | MTNR1A (0.62) | MTNR1ANQO2HTTHPGDCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041225-A1 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | VAIDYA NITEEN A (US) | 2012-02-16 | — | — | US | claimed |
| EP-1981831-A2 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | Vaidya, Niteen A. (US) | 2008-10-22 | — | — | EP | claimed |
| WO-2007092264-A2 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | VAIDYA NITEEN A (US) | 2007-08-16 | — | — | WO | claimed |
| US-20070185346-A1 | Kit for automated resolving agent selection and method thereof | VAIDYA NITEEN A | 2007-08-09 | — | — | US | claimed |
| EP-4397674-A1 | CASPASE-2 INHIBITOR COMPOUNDS | Kintsugi Therapeutics S.L. (ES) | 2024-07-10 | — | — | EP | disclosed |
| WO-2022268066-A1 | PROTEIN DEGRADATION AGENT | 苏州开拓药业股份有限公司 | 2022-12-29 | — | — | WO | disclosed |
| US-10723727-B2 | Tubulysin analogs and methods for their preparation | PFIZER INC. (US) | 2020-07-28 | — | — | US | disclosed |
| EP-3092244-B1 | DIPEPTIDES AS INHIBITORS OF HUMAN IMMUNOPROTEASOMES | UNIV CORNELL (US) | 2019-08-14 | — | — | EP | disclosed |
| EP-2719384-B1 | Novel 1-naphthyl-3-azabicyclo[3.1.0]hexanes:preparation and use to treat neuropsychiatric disorders | OTSUKA AMERICA PHARMACEUTICAL INC (US) | 2018-08-08 | — | — | EP | disclosed |
| US-10017481-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2018-07-10 | — | — | US | disclosed |
| US-10017481-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2018-07-10 | — | — | US | disclosed |
| US-20180186808-A1 | NARGENICIN COMPOUNDS AND USES THEREOF AS ANTIBACTERIAL AGENTS | MERCK SHARP & DOHME LLC | 2018-07-05 | — | — | US | disclosed |
| US-20030181470-A1 | Heterocyclic compounds and uses thereof as D-alanyl-D-alanine ligase inhibitors | ESSENTIAL THERAPEUTICS, INC. | 2003-09-25 | — | — | US | disclosed |
| WO-2003001887-A2 | FUSED PYRIMIDINES AS D-ALANYL-D-ALANINE LIGASE INHIBITORS | ESSENTIAL THERAPEUTICS, INC. (US) | 2003-01-09 | — | — | WO | disclosed |
| EP-1073633-A2 | SUBSTITUTED BETA-AMINO ACID INHIBITORS OF METHIONINE AMINOPEPTIDASE-2 | ABBOTT LABORATORIES (US) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999057098-A2 | SUBSTITUTED BETA-AMINO ACID INHIBITORS OF METHIONINE AMINOPEPTIDASE-2 | ABBOTT LABORATORIES (US) | 1999-11-11 | — | — | WO | disclosed |
| US-5453163-A | Electrokinetic packing of capillary columns | ASHLAND LICENSING AND INTELLECTUAL PROPERTY LLC | 1995-09-26 | — | — | US | disclosed |
| EP-0259793-B1 | NAPHTHYL DERIVATIVES, MEDICAMENTS CONTAINING THEM AND PROCESSES FOR THEIR PREPARATION | Dr. Karl Thomae GmbH (DE) | 1992-07-01 | — | — | EP | disclosed |
| US-5089046-A | Herbicides or miticide | SANDOZ LTD. (CH) | 1992-02-18 | — | — | US | disclosed |
| US-4871735-A | HYPOTENSIVE, ANTIISCHEMIC AGENTS | DR. KARL THOMAE GMBH | 1989-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186808-A1 | NARGENICIN COMPOUNDS AND USES THEREOF AS ANTIBACTERIAL AGENTS | NRDC, MME, NME2 | MTNR1A 2624/4885NQO2 9/4885TAAR1 2735/4885 |
| US-20120041225-A1 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | ACKR3, KIT, C3AR1 | MTNR1A 2437/4885NQO2 3002/4885TAAR1 2357/4885 |
| US-20030181470-A1 | Heterocyclic compounds and uses thereof as D-alanyl-D-alanine ligase inhibitors | AAAS, ALAD, NAALAD2 | MTNR1A 4806/4885NQO2 1122/4885TAAR1 4400/4885 |
| US-10017481-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | CTSE, CTSB, CTSS | MTNR1A 563/4885NQO2 4395/4885TAAR1 151/4885 |
| US-10723727-B2 | Tubulysin analogs and methods for their preparation | NGLY1, TEK, TEKT1 | MTNR1A 3423/4885NQO2 2979/4885TAAR1 3354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.